Atlas Trials

Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)

Clinical trial NCT01284582 · COMPLETED

Trial details

NCT number
NCT01284582
Sponsor
Affiris AG
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
HDLDrug Safety
Start date
2011-05-01
Primary completion
2012-07-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.